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Abstract
Background: Histiocytic sarcoma affecting the central nervous system (CNS HS) in dogs
may present as primary or disseminated disease, often characterized by inflammation.
Prognosis is poor, and imaging differentiation from other CNS tumors can be problematic.
Objective: To characterize the clinicopathological inflammatory features, breed pre-
disposition, and survival in dogs with CNS HS.
Animals: One hundred two dogs with HS, 62 dogs with meningioma.
Methods: Retrospective case series. Records were reviewed for results of cerebro-
spinal fluid (CSF) analysis, CBC, treatment, and outcome data.
Results: Predisposition for CNS HS was seen in Bernese Mountain Dogs, Golden
Retrievers, Rottweilers, Corgis, and Shetland Sheepdogs (P ≤ .001). Corgis and Shet-
land Sheepdogs had predominantly primary tumors; Rottweilers had exclusively dis-
seminated tumors. Marked CSF inflammation was characteristic of primary rather
than disseminated HS, and neoplastic cells were detected in CSF of 52% of affected
dogs. Increased neutrophil to lymphocyte ratios were seen in all groups relative to
controls (P <.008) but not among tumor subtypes. Definitive versus palliative treat-
ment resulted in improved survival times (P < .001), but overall prognosis was poor.
Conclusions and Clinical Importance: Clinicopathological differences between pri-
mary and disseminated HS suggest that tumor biological behavior and origin may be
different. Corgis and Shetland Sheepdogs are predisposed to primary CNS HS, char-
acterized by inflammatory CSF. High total nucleated cell count and the presence of
neoplastic cells support the use of CSF analysis as a valuable diagnostic test. Progno-
sis for CNS HS is poor, but further evaluation of inflammatory mechanisms may pro-
vide novel therapeutic opportunities.
K E YWORD S
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Abbreviations: APC, antigen presenting cell; CI, confidence interval; CNS, central nervous system; CSF, cerebrospinal fluid; HS, histiocytic sarcoma; IQR, interquartile range; MST, median survival
time; N:L, neutrophil to lymphocyte ratio; RBC, red blood cell; TNCC, total nucleated cell count; TP, total protein concentration.
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1 | INTRODUCTION
Histiocytic sarcomas (HS) are tumors that arise typically from
interstitial dendritic cells1,2 and may occur as localized disease or
as disseminated disease affecting multiple organs. Several dog
breeds are consistently overrepresented in HS case series, and a
familial association has been reported in Bernese Mountain
Dogs.3-5 Defined breed predisposition data for HS are limited, but
Bernese Mountain Dog, Golden Retriever, Flat Coat Retriever, Shar
Pei, Miniature Schnauzer, Labrador Retriever, and Pembroke Welsh
Corgi breeds have been shown to be overrepresented based on
defined control populations,6,7 and Rottweilers are conspicuously
overrepresented in several case series.1,8-11 Histiocytic sarcoma
involving the central nervous system (CNS) is relatively uncommon
representing 2.2% (n = 2) of primary and 3.4% (n = 7) of secondary
intracranial neoplasms diagnosed at necropsy,12 and prognosis
regardless of treatment is anecdotally poor.13-15 Intracranial CNS
HS commonly are reported as extra-axial, uniformly contrast-
enhancing masses on magnetic resonance (MR) imaging, and differ-
entiation from more commonly occurring, and generally more
benign extra-axial tumors such as meningioma can be
challenging.13,16,17
The majority of published data about CNS HS relates to pri-
mary, localized CNS HS in small case series,13-19 with limited avail-
ability of defined breed predisposition data.13 Pembroke Welsh
Corgis, Shetland Sheepdogs, Labrador Retrievers, and Golden
Retrievers were overrepresented relative to total hospital population
in 1 study,13 and Corgis also were noted at higher frequencies in
other uncontrolled studies.18,19 Central nervous system HS appear
to differ from HS in most other organs in the severity of inflamma-
tory infiltrate,2,13,15,18,19 but it is unclear whether this inflammatory
phenotype is common to all CNS HS or if it is restricted to primary
localized disease. Markedly increased total nucleated cell counts
(TNCC) have been reported in cerebrospinal fluid (CSF) from CNS
HS cases.13,20,21 This observation likely reflects the inflammatory
component of the disease and is in contrast to most other primary
CNS tumors in which normal to mildly increased CSF cell counts are
typical.22-24
To further evaluate the inflammatory nature of CNS HS
in dogs, a clinicopathological review of a series of primary and dis-
seminated CNS HS cases and meningiomas was done. Markers
of inflammation in CSF (TNCC) and peripheral blood (leukocyte
neutrophil to lymphocyte [N:L] ratio) were defined in the context
of tumor subtype (primary or disseminated CNS HS, meningioma)
to determine potential relevance to diagnostic and prognostic
criteria.
2 | MATERIALS AND METHODS
This was a retrospective investigational study conducted at the Uni-
versity of California (UC) Davis School of Veterinary Medicine and
Department of Small Animal Clinical Sciences, Virginia Maryland
College of Veterinary Medicine. Medical records were reviewed for
cases with a primary inclusion criterion of a histopathological diagno-
sis of HS affecting the CNS. Definitive classification as primary CNS
(either as a solitary mass or multifocal disease restricted to the CNS)
or disseminated (CNS disease with evidence of other organ system
involvement) required full necropsy including the CNS. Cases were
classified as brain or spinal cord based on primary neuroanatomical
localization at presentation. Additional clinical and clinicopathological
data were collected including signalment, clinical history, CSF analysis,
CBC, treatment history, and survival.
2.1 | Pathology
Diagnosis of HS was made by a board-certified pathologist (R.J.H. or
K.W.) based on previously described histopathological and
immunophenotypic features.1,2
2.2 | Breed predisposition
Overrepresentation of HS in specific breeds was determined only for
dogs diagnosed with CNS HS (n = 91) admitted to the UC Davis Vet-
erinary Medical Teaching Hospital (VMTH) compared to the total UC
Davis VMTH reference population (n = 222 814) during the study
period (1986-2018).
2.3 | CSF analysis
Cerebrospinal fluid analyses were included from cases in which sam-
ples were acquired at first presentation, before specific treatment.
The CSF collection site was noted when available. Any corticosteroid
administration within 1 week of CSF analysis was noted. Total nucle-
ated cell counts, total protein concentration (TP), RBC counts, and dif-
ferential counts were performed within 30 minutes of collection of
CSF as previously described.23 Three cases of HS CSF analysis (pri-
mary brain cases 14, 30; primary spinal cord case 5) and 56 reference
CSF analyses from intracranial meningioma cases were reported previ-
ously.21,23,25 Cytocentrifuge Wright's or Wright's-Giemsa stained
preparations were retrospectively reviewed by 2 board-certified clini-
cal pathologists (W.V., K.Z.) for the presence of neoplastic cells and
mitotic figures.
2.4 | Neutrophil to lymphocyte (N:L) ratio
Inclusion criteria for N:L ratios were the same as for CSF analysis.
Complete blood counts from cases that had received corticosteroids
within 1 week of presentation were excluded from analysis. Only
VMTH cases were included, and reference values for N:L ratios were
calculated from raw CBC reference interval data from the UC Davis
VMTH clinical laboratory.
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2.5 | Treatment and outcome
Treatment groups were defined as definitive if specific treatment
modalities including surgical resection, radiation treatment, or chemo-
therapy (specifically lomustine) were used in any combination, and palli-
ative if anti-inflammatory (non-steroidal), corticosteroid, antiepileptic, or
other analgesic medications were the only therapeutic interventions.
Survival was defined for all cases from time of presentation with neuro-
logical signs, and only for cases with survival times >1 day to exclude
animals euthanized at the time of imaging or diagnosis.
2.6 | Statistical analysis
To define breed predisposition, a Fisher's exact test was used to com-
pare the distribution of HS within each breed relative to the entire
population of dogs admitted to the UC Davis VMTH during the retro-
spective period, and the corresponding odds ratios were presented
with surrounding 95% confidence intervals (CI).
Continuous variables were assessed for normal distribution using a
combined test of skewness and kurtosis. Rates of steroid administration
were compared between groups using Fisher's exact test. Cerebrospinal
TABLE 1 Breed predisposition for CNS HS (breeds with ≥3 CNS HS)
Breed Hospital % Histiocytic % Primary Dissem Undet Exact P value OR (95% CI)
Bernese Mountain Dogs 0.5 8.8 2 6 0 <.001 21.0 (10.1-43.8)
Corgi 0.7 5.5 3 0 2a .001 8.3 (3.4-20.5)
Golden Retriever 4.6 14.3 4 6 3b <.001 3.5 (1.9-6.2)
Labrador 8.8 4.4 2 2 0 .19 0.5 (0.2-1.3)
Labrador Cross 3.1 3.3 1 1 1a .76 1.1 (0.3-3.3)
Rottweiler 2.6 15.4 0 14 0 <.001 6.9 (3.9-12.2)
Shetland Sheepdog 0.9 5.5 3 1 1 .001 6.8 (2.7-16.7)
Abbreviations: CI, confidence interval; CNS HS, histiocytic sarcoma affecting the central nervous system; Dissem, disseminated; OR, odds ratio; Sig,
significance P value; Undet, undetermined.
aNormal physical examination, thoracic radiographs and abdominal ultrasound.
bNormal physical examination, thoracic radiographs and abdominal ultrasound (1), multifocal abdominal disease (1), no data (1).
F IGURE 1 A and B, Box plots of CSF total nucleated cell counts in primary CNS HS, disseminated CNS HS and meningiomas, regardless of
corticosteroid administration. B, Expanded TNCC scale to allow assessment of low TNCC data points in disseminated CNS HS and meningioma
groups. Boxes correspond to interquartile ranges (25th–75th percentiles); the horizontal line within the box is the median value (50th percentile).
Whiskers represent lower and upper adjacent values (i.e. the lowest and highest observations that are still inside the region defined by the
following limits: Lower limit: Q1−1.5 × IQR. Upper limit: Q3 + 1.5 × IQR). Significant differences between tumor groups are indicated by
brackets. IQR, interquartile range
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fluid, TP, TNCC, and CBC N:L ratios were compared according to steroid
administration status within the overall population and within histiocytic
and meningioma subgroups using Wilcoxon rank sum tests. Among all
dogs, and in the subset with no corticosteroid administration, CSF TP,
CSF TNCC, and CBC N:L ratios were compared across tumor subgroups
(primary HS, disseminated HS, meningioma) using Dunn's test of multi-
ple comparisons using rank sums. Overall survival time measured from
clinical presentation was estimated using the Kaplan-Meier product limit
method. Dogs alive or lost to follow-up at the time of data collection
were censored in analyses. Rates of definitive versus palliative treat-
ment were compared between primary and disseminated HS cases
using Fisher's exact test. Survival estimates were compared according to
treatment type (definitive versus palliative) overall and within primary
and disseminated HS groups. All tests were 2-sided, and P < .05 was
considered statistically significant.
3 | RESULTS
3.1 | Signalment
Between 1986 and 2018, 102 dogs were identified with a histopathologi-
cal diagnosis of CNS HS (Data S1). Tumors consisted of 33 primary brain
HS (2 male, 15 castrated male, 16 spayed female; median age, 8.0 years;
range, 4.0-12.0 years), 8 primary spinal cord HS (1 female, 4 castrated
male, 3 spayed female; median age, 8.0 years; range, 6.0-10.0 years),
20 disseminated brain HS (1 male, 2 female, 9 castrated male, 8 spayed
female; median age, 8.5 years; range, 4.0-13.0 years), 25 disseminated
spinal cord HS (6 male, 6 castrated male, 13 spayed female; median age,
9.0 years; range, 2.0-12.0 years), 14 brain HS with no necropsy (1 male,
1 female, 8 castrated male, 4 spayed female; median age, 9.5 years; range,
3.0-13.0 years), and 2 spinal cord HS with no necropsy (1 castrated male,
3 years age; 1 spayed female, 9 years age). For all CNS HS tumors com-
bined (10 male, 4 female, 43 castrated male, 45 spayed female), the
median age was 8.0 years (range, 2.0-13.0 years). No consistent trend in
increasing frequency of CNS HS was seen over the retrospective time
period (Data S2); total number of CNS HS (VMTH) cases and their per-
centage of the total hospital population were 1986-1996 (14, 0.024%);
1997-2007 (45, 0.063%); 2008-2018 (31, 0.034%).
Breed predisposition was determined from 91 cases presented
to the UC Davis VMTH with a control hospital population of
222 814 dogs during the study period. Seven breeds had ≥3 CNS HS
(Table 1) and represented 57% of all CNS HS cases. Breed predispo-
sition was found in Bernese Mountain dogs, Golden Retrievers, Rott-
weilers, Shetland Sheepdogs, and Corgis. Corgis and Shetland
Sheepdogs had predominantly primary CNS HS, whereas Rottweilers
had exclusively disseminated CNS HS. In the uncontrolled cases
(Virginia Maryland, n = 11), 3/6 primary CNS HS were in Corgis (2/6)
and a Shetland Sheepdog, and 2/5 disseminated CNS HS were in
Rottweilers.
F IGURE 2 A and B, Box plots of CSF total protein in primary CNS HS, disseminated CNS HS and meningioma. A, All cases regardless of
corticosteroid administration. B, Cases with no history of corticosteroid administration. Boxes correspond to interquartile ranges (25th–75th
percentiles); the horizontal line within the box is the median value (50th percentile). Whiskers represent lower and upper adjacent values (i.e. the
lowest and highest observations that are still inside the region defined by the following limits: Lower limit: Q1−1.5 × IQR. Upper limit: Q3 + 1.5 ×
IQR). Significant differences between tumor groups are indicated by brackets. Outlying data points are included with values in brackets. IQR,
interquartile range
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For HS affecting the brain, the majority of tumors were located
rostrotentorially. For primary HS there were 19 solitary and 6 multifocal
or diffuse rostrotentorial tumors; 2 solitary and 3 multifocal or diffuse
infratentorial tumors; 3 tumors affecting both compartments, and 3 of
the tumors also had intraventricular involvement. Three tumors also had
spinal cord involvement. For disseminated HS affecting brain, there
were 9 solitary and 4 multifocal or diffuse rostrotentorial tumors; 3 soli-
tary infratentorial tumors; 3 tumors affecting both compartments; and
2 tumors that involved peripheral cranial nerves (1 with cranial nerves
III, IV, V, 1 with cranial nerves III, IV). Two tumors also had spinal cord
involvement. Based on MR imaging, involvement of both meninges and
brain parenchyma was a consistent finding for intracranial HS and most
tumors had broad areas of meningeal contact. All intraventricular tumors
were found in animals with multifocal disease, and 1 disseminated
tumor involved only cranial nerves III, IV, and V with no parenchymal
involvement.
For HS affecting the spinal cord, 7/8 primary HSs were intrinsic
compared to disseminated HS where 24/25 tumors were extradural.
Vertebral bone involvement was documented in 14/25 of the dissemi-
nated tumors with extradural lesions. No apparent regional predisposi-
tion was seen with primary HS (2 cervical, 3 thoracic, 2 lumbar,
1 multifocal), but disseminated HS was most common in the thoracic
region (3 cervical, 11 thoracic, 6 lumbar, 5 multifocal of which 3 involved
thoracic segments). One primary and 2 disseminated tumors also
involved brain.
3.2 | CSF analysis
Cerebrospinal fluid analysis was available for 24 primary CNS HS
(17 brain, 7 spinal cord) and 17 disseminated CNS HS (6 brain, 11 spi-
nal cord) cases (Figures 1–3; Data S3). Cerebrospinal fluid was col-
lected from the cerebellomedullary cistern in 40/41 brain HS cases
with sampling site not noted in 1 case. Cerebrospinal fluid from spinal
cord HS cases was collected from the lumbar subarachnoid space in
16/18 and cerebellomedullary cistern in 2/18 cases (Data S3). Total
nucleated cell counts were available for all cases, and CSF TP was avail-
able for 39/41 samples. Median RBC count for CNS HS was 20 RBC/
μL (range, 0-3900 μL) and 4 RBC/μL (range, 0-3300 μL) for meningioma
samples. Cerebrospinal fluid-related corticosteroid administration status
was reported for all cases, and the rate of corticosteroid administration
did not differ significantly (P = .58) between HS (12/41, 29.3%) and
meningioma (18/62, 29%) cases.
Median CSF TNCC did not differ significantly based on the pres-
ence or absence of corticosteroid administration for both HS and
meningiomas groups (P = .12, P = .67, respectively). Median CSF
TNCC differed significantly (P < .001) across tumor types (Figure 1).
Cerebrospinal fluid TNCC was significantly higher in 24 dogs with pri-
mary HS (median, 170; interquartile range [IQR], 48-902) compared to
17 dogs with disseminated HS (median, 4; IQR, 1-11; P < .001) and
62 dogs with meningioma (median, 2; IQR, 1-5; P < .001). No signifi-
cant difference (P = .09) was found between the disseminated HS and
meningioma groups.
Median CSF TP differed significantly (P = .02) between HS cases
that received steroids (209 mg/dL; IQR, 72-445) and HS cases that
did not (82 mg/dL; IQR, 51-130). Median TP of CSF did not differ
F IGURE 3 Cerebrospinal fluid cytospin preparations from dogs
with primary CNS HS. A, Note the three extremely large, neoplastic,
single round cells with large immature and atypical nuclei, admixed
with numerous inflammatory cells comprising nondegenerate
neutrophils and macrophages. B, There are two large neoplastic
histiocytes, one of which is mitotic, admixed with numerous
inflammatory cells. C, There is a markedly increased total nucleated cell
count (TNCC) and numerous mitoses, which raises the index of
suspicion for underlying primary CNS HS and should prompt a search
for large, atypical round cells. Wright's-Giemsa stain, scale bar = 10 μm
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significantly (P = .75) for meningioma cases based on corticosteroid
administration. For all dogs, CSF TP differed significantly (P < .001)
across tumor types (Figure 2). Median CSF TP was significantly lower
in meningioma (median, 36 mg/dL; IQR, 22-77) compared to primary
HS (median, 123 mg/dL; IQR, 69-269; P < .001) and disseminated HS
(median, 80 mg/dL; IQR, 45-128; P = .003). No significant difference
(P = .12) was found between primary and disseminated HS groups.
Significance conclusions remained unchanged when CSF TP concen-
tration analysis was restricted to cases with no corticosteroid adminis-
tration (P < .001, P = .006, P = .34, respectively).
Neoplastic cells were identified in 52% (9/18 primary CNS HS,
4/7 disseminated CNS HS) of cytological preparations for which slides
were available for review (Figure 3). Neoplastic cells were identified in
3 samples in which they had not been identified in the initial report.
Mitoses were present in 10 samples and only were seen in cases
where neoplastic cells also were identified (Figure 3).
3.3 | Neutrophil to lymphocyte ratio
Among dogs that did not receive corticosteroids, N:L did not differ sig-
nificantly (P = .08) across tumor types (primary HS, disseminated HS,
and meningioma). Median N:L ratio was 4.2 (IQR, 3.7-8.4) in 12 dogs
with primary HS, 8.6 (IQR, 5.5-20.8) in 21 dogs with disseminated HS,
and 7.7 (IQR, 5.4-12.0) in 42 dogs with meningioma. Median N:L ratio
in 60 control dogs (2.6; IQR, 1.8-2.9) was significantly lower than in the
primary HS (P = .007), disseminated HS (P < .001), and meningioma
groups (P < .001; Figure 4).
3.4 | Treatment outcome
Survival time after presentation for neurological signs was available
for 96 of 102 cases (33 primary brain, 8 primary spinal cord, 19 dis-
seminated brain, 24 disseminated spinal cord, 10 brain without nec-
ropsy, and 2 spinal cord without necropsy). Ninety-four dogs died and
2 were lost to follow-up. Treatment modalities and survival data are
outlined in Data S1. Median survival time (MST) for all 96 dogs was
4 days (95% CI, 2-8 days). Thirty-three dogs (all with palliative or no
treatment) survived <1 day and were excluded from further analysis
to remove cases without intent to treat. Definitive treatments were
done in 27 cases (12 primary HS, 8 disseminated HS, and 7 undefined
HS), and palliative treatment in 36 cases (17 primary HS, 15 dissemi-
nated HS, and 4 undefined HS). Among dogs surviving >1 day, defini-
tive treatment (MST, 44 days; 95% CI, 17-97) was associated with
significantly (P < .001) longer survival compared with palliative treat-
ment (MST, 5 days; 95% CI, 3-22) (Figure 5). Within this population,
significantly longer survival times also were seen when comparing
F IGURE 4 Boxplots of peripheral CBC neutrophil:lymphocyte
ratios from cases of primary CNS HS, disseminated CNS HS,
meningioma and control (clinically normal) dogs. Whiskers represent
+/- 1.5 interquartile ranges. Significant differences between tumor
groups are indicated by asterisks. Boxes correspond to interquartile
ranges (25th–75th percentiles); the horizontal line within the box is
the median value (50th percentile). Whiskers represent lower and
upper adjacent values (i.e. the lowest and highest observations that
are still inside the region defined by the following limits: Lower limit:
Q1−1.5 × IQR. Upper limit: Q3 + 1.5 × IQR). Significant differences
between tumor groups are indicated by brackets. Outlying data points
are included with values in brackets. IQR, interquartile range
F IGURE 5 Kaplan-Meier survival estimates for definitively and
palliatively treated histiocytic sarcoma affecting the central nervous
system (CNS HS) (primary and disseminated) cases that
survived >1 day
TOYODA ET AL. 833
definitively vs palliatively treated primary HS (P < .008; MST, 43 days;
95% CI, 5-127 vs MST, 5 days; 95% CI, 2-8) and definitively vs pallia-
tively treated disseminated HS (P = .03; MST, 27 days; 95% CI, 8-146
vs MST, 4 days; 95% CI, 2-14).
4 | DISCUSSION
Our study defines hospital population-based breed predispositions for
HS affecting the CNS in dogs and defines several clinicopathological
characteristics that suggest primary and disseminated HS may have
different pathophysiology in the context of CNS disease. Primary and
disseminated CNS HS were shown to differ in terms of inflammatory
response based on CSF analysis, different breed predisposition, and
different anatomical locations of disease, particularly with disease
affecting the spinal cord.
The presence of breed predisposition for HS affecting the CNS
likely represents underlying genetic susceptibilities, but disease-
related factors may be complex, reflecting not only susceptibility to
HS in general but also to development of primary versus disseminated
CNS disease. This complexity is apparent in our data in which larger
populations of primary and disseminated CNS HS were analyzed.
Corgis have been reported to have a high frequency of HS affecting
tissues outside the CNS7 and also HS affecting the CNS.13,18,19
Although limited in numbers, these data and ours suggest that CNS
HS in Corgis rarely is associated with disseminated disease, although
extra-CNS disease frequently is reported. This observation is in stark
contrast to CNS HS in Rottweilers that accounted for the highest
number of HS in our study (16/102, 16%) and where all tumors were
associated with disseminated disease outside the CNS as well. Previ-
ous reports of CNS HS in Rottweilers also are consistent with dissemi-
nated disease,11,18,26,27 and this phenotypic variation likely reflects
different HS tumor biology in the different groups.
The underlying cell of origin may be different for primary versus
disseminated CNS HS. The term histiocyte covers a spectrum of cell
types including dendritic antigen presenting cells (APC) or those of
macrophage origin.28 Most extra-CNS HS are thought to be of mye-
loid dendritic APC (interstitial dendritic cell) origin based on their
immunophenotype.1 The origin of primary CNS HS in dogs is poorly
defined, with conflicting reports of expression of both interstitial den-
dritic cell and macrophage phenotypes.2,18,19,29 Definition of dendritic
APC and macrophage lineages is complex and controversial and com-
monly used phenotypic markers (eg, CD1, CD11c, CD11b, CD11d,
MHCII) may fail to distinguish dendritic cells from monocytes, macro-
phages, and even activated microglia, particularly in non-lymphoid
organs.30 Interstitial dendritic cells generally are not thought to be
present within the brain, but dendritic cells have been reported in the
meninges, choroid plexus, and circumventricular organs.31 Adding to
this complexity, infiltrating inflammatory monocytes or macrophages
and subpopulations of resident microglia also may differentiate into
dendritic cells within the CNS.32,33 Defining the cellular origin of spe-
cific CNS histiocytic tumor subgroups will be important for appropriate
tumor phenotyping for future genetic studies and for development of
appropriately targeted novel therapeutic approaches with respect to
what may be 2 distinct tumors.
The previously reported predisposition in Labrador Retrievers
was not confirmed in our study, but the suspected predisposition in
Shetland Sheepdogs as proposed previously13 was confirmed. Minia-
ture Schnauzers have been shown to be predisposed to HS in non-
CNS cases,6 and multiple single cases affecting the CNS have been
reported.14,18,19,34,35 Only 2 Miniature Schnauzers were reported in
our series, both with disseminated disease, with no defined breed pre-
disposition based on this limited number of cases.
Primary CNS HS was associated with an inflammatory pheno-
type compared to disseminated CNS HS (and meningioma) based on
CSF TNCC. We can speculate that the specific cell lineage of primary
versus disseminated disease is associated with a more pro-
inflammatory phenotype, but other factors may be associated with
anatomical localization of the neoplastic process. Primary HS spinal
cord tumors were predominantly intrinsic compared to extradural
disseminated tumors, and a logical argument can be made that these
primary tumors would be more likely to stimulate an inflammatory
response, reflected in CSF pleocytosis within the subarachnoid
space. However, other intrinsic and intradural spinal cord tumors
generally are not associated with the marked pleocytosis seen with
primary CNS HS,36,37 making anatomical location unlikely to be the
only factor. In the absence of a defined intracranial subdural space,
both primary and disseminated HS involve both the meninges and
the brain parenchyma, and most other intracranial neoplasia is not
associated with marked CSF pleocytosis,22-24 also supporting an
argument for inherent differences in the pro-inflammatory nature of
the primary versus disseminated HS subtypes. Articular or peri-
articular HS also has been associated with a marked inflammatory
response,8 and associations have been made between prior injury
and inflammation involving the joint and the development of HS.38,39
No direct evidence supports underlying inflammation as a
predisposing factor for the development of HS, but the link between
inflammation and a variety of cancers is well documented.40 Further
investigation is warranted to determine whether preexisting inflam-
mation may be a precursor for primary CNS HS and whether specific
breeds may have genetic predispositions consistent with this patho-
genic mechanism.
Systemic inflammatory responses associated with cancer are well
documented, and increases in peripheral blood N:L ratios have been
used widely as an indicator of tumor-associated inflammation.41
Increased N:L ratios have been associated with poorer overall survival
in a variety of cancers in humans,42 including intracranial gliomas.43
The N:L ratios were significantly increased in all tumor subgroups in
our study compared to normal reference ranges, but the marked pro-
inflammatory phenotype of primary versus disseminated CNS HS
reflected in the CSF TNCC was not apparent in peripheral blood N:L
ratio findings. Although no significant differences were found among
the relatively low number of samples in the different tumor groups, the
disseminated HS and meningioma N:L ratios (median, 8.6 and 7.7,
respectively) were higher than in the primary HS group (median, 4.2).
Specific underlying mechanisms driving cancer-derived systemic
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inflammation are poorly understood, and the anatomical location of
the primary HS tumors or lack of systemically acting, tumor-related
factors may contribute to a lesser systemic response compared to that
of the disseminated HS and meningiomas. The presence of neoplastic
cells in CSF did not appear to be related to the severity of CSF
pleocytosis, and neoplastic cells were identified in both primary and
disseminated HS CSF samples. Although mitoses may be seen in non-
neoplastic CSF-nucleated cells, they are uncommon, and the strong
association of mitoses with the presence of neoplastic cells in HS is
notable. Utility of CSF as a diagnostic tool for intracranial mass lesions
is not always appreciated, but the markedly high incidence (>50%) of
diagnostic atypical cells, and the significant difference in CSF TNCCs
between primary HS and meningiomas underscores the value of CSF
analysis when imaging-based data are suggestive of these tumor types
as primary differential diagnoses. Interestingly, all 3 CSF samples con-
taining tumor cells that were not identified on initial examination had
both markedly increased TNCC and scattered mitoses, which, in the
appropriate clinical context, should increase the index of suspicion for
primary CNS HS and the presence of neoplastic cells, respectively. The
presence of eosinophils was a common finding in CNS HS CSF (35%),
but this finding was not specific for an HS subtype and also was seen
in CSF samples of meningioma cases, as reported previously.23 Corti-
costeroid usage and dosage were variable among cases, but this differ-
ence likely did not detract from overall conclusions related to CSF
pleocytosis and survival data. Counterintuitively, HS cases that
received corticosteroids had significantly higher CSF TP, and although
not significant, CSF TNCC also was higher in the steroid administration
HS group. This finding may be reflective of a higher number of primary
(and more likely inflammatory) cases (8/41 versus 3/41 disseminated
HS cases) receiving corticosteroids, possibly associated with more
severe clinical signs.
Limited data are available regarding treatment and survival for
dogs with CNS HS, but anecdotal reports suggest prognosis is generally
poor. Case series of CNS HS with >3 dogs have reported MST of
3 days (n = 19),13 14 days (n = 4),14 and 30 days (n = 5)15 with no dis-
tinction between definitive and palliative treatment. Low sample num-
bers and marked variability in tumor locations and treatment modalities
preclude any detailed analysis of therapeutic outcome in our study, but
general comments can be made. Median survival for all dogs for which
data were available (n = 96) was similar to previous reports at 4 days,
but 30 dogs had survival times of 1 day. Removing these (presumably
euthanized at diagnosis) cases resulted in median survivals of 44 days
for definitively (surgery, radiation therapy, lomustine chemotherapy)
treated cases (n = 27) and 5 days for palliative or no treatment cases
(n = 36). “Dedicated owner” effects are likely to have affected the
definitively treated survival outcomes, but the maximum documented
survival time still was <8 months in a dog with a primary intracranial
HS treated with surgery and lomustine, and only 8 of 96 dogs had sur-
vival times >4 months. Primary CNS HS is an extremely rare tumor in
humans and carries a similarly poor prognosis with survival after defini-
tive therapy typically <1 year.44,45 Limited data are available to define
the incidence of primary versus secondary CNS HS in humans, but
most reports involve primary tumors. Interestingly, a marked
inflammatory infiltrate also has been described for these primary
tumors in humans similar to their counterparts in dogs,46-49 suggesting
that they may have some common underlying characteristics.
Our study conclusions are limited by relatively small sample sizes
in tumor and treatment subgroups, variability in defined survival end
points and potential for inappropriate categorization of primary
tumors, even with comprehensive necropsy examination. However,
the significant differences defined between primary and disseminated
CNS HS particularly in terms of breed predisposition and inflamma-
tory response within the CNS are notable. Advances in treatment of a
variety of cancers in humans by manipulation of inflammatory and
associated immune-cell modulation have resulted in new optimism
about several previously intractable cancers. Primary CNS HS in dogs
appears to carry a poor prognosis regardless of standard therapeutic
interventions. Further evaluation of the inflammatory environment
present in these tumors may provide critical insight into the biology of
CNS HS in dogs and the potential for the development of novel thera-
peutic approaches.
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